Table 4.
Ongoing combination therapy with mTOR inhibitors in different cancers
| Tumor type | Ongoing combination trial | ||
|---|---|---|---|
| Intervention/treatment | Study ID number | Phase | |
| Breast | |||
| Marketed: metastatic, HR + /HER2 − breast cancer (Everolimus) | |||
| Luminal A (HR + /HER −) | AZD2014/Everolimus + Fulvestrant | NCT02216786 | Phase II |
| Everolimus + Paclitaxel | NCT04355858 | Phase II | |
| HER + (HR − /HER +) | Rapamycin + Inetetamab + Chemotherapy | NCT04736589 | Phase III |
| TN | AZD2014 + AZD6244 (MEKI) | NCT02583542 | Phase I/II |
| Everolimus + Bevacizumab + Doxorubicin | NCT02456857 | Phase II | |
| Others | Temsirolimus + AZD6244 | NCT00600496 | Phase I |
| Colorectal | |||
| Nab-rapamycin + FOLFOX6 + Bevacizumab | NCT03439462 | Phase I/II | |
| Temsirolimus + AZD6244 | NCT00600496 | Phase I | |
| Lung | |||
| Marketed: sporadic lymphangioleiomyomatosis (rapamycin) | |||
| NSCLC | Gedatolisib + Palbociclib | NCT03065062 | Phase I |
| Rapamycin + Epacadostat | NCT03217669 | Phase I | |
| AZD2014 + AZD6244 (MEKI) | NCT02583542 | Phase I/II | |
| Sirolimus + Durvalumab | NCT04348292 | Phase I | |
| NSCLC + SCLC | Rapamycin + Auranofin | NCT01737502 | Phase I/II |
| Temsirolimus + AZD6244 | NCT00600496 | Phase I | |
| Head and neck | |||
| Gedatolisib + Palbociclib | NCT03065062 | Phase I | |
| Urogenital | |||
| Temsirolimus + Paclitaxel + Carboplatin | NCT00977574 | Phase II | |
| AZD2014 + Anastrozol | NCT02730923 | Phase I/II | |
| Rapamycin + Auranofin | NCT03456700 | Phase II | |
| Everolimus + Levonorgestrel | NCT02397083 | Phase II | |
| Everolimus + Letrozole + Ribociclib | NCT03008408 | Phase II | |
| ATG008/ATG010 | NCT04998760 | Phase II | |
| Leukemia | |||
| Decitabine + Rapamycin | NCT02109744 | Phase I/II | |
| Rapamycin + Azacitidine | NCT01869114 | Phase II | |
| Rapamycin + Tacrolimus + Melphalan + Clofarabine | NCT01885689 | Phase II | |
| Lymphoma | |||
| Marketed: mantle cell lymphoma (temsirolimus) | |||
| Hodgkin | Everolimus + Itacitinib | NCT03697408 | Phase I/II |
| Pancreatic | |||
| Gedatolisib + Palbociclib | NCT03065062 | Phase I | |
| Renal | |||
| Marketed: metastatic renal cancer (everolimus, temsirolimus) | |||
| Temsirolimus + Sunitinib | NCT01517243 | Phase II | |
| Temsirolimus + AZD6244 | NCT00600496 | Phase I | |
| Everolimus + DFF332 (HIF2αI) | NCT04895748 | Phase I | |
| Everolimus + Lenvatinib | NCT03324373 | Phase I | |
| Everolimus + Lenvatinib | NCT05012371 | Phase II | |
| Brain, CNS | |||
| Marketed: astrocytoma (everolimus) | |||
| Temsirolimus + Perifosine | NCT02238496 | Phase I | |
| Temsirolimus + Vorinostat | NCT02420613 | Phase I | |
| Nab-rapamycin + Temozolomide + Irinotecan | NCT02975882 | Phase I | |
| Temsirolimus + Dasatinib + Cyclophosphamide | NCT02389309 | Phase I | |
| Nab-rapamycin + standard therapy | NCT03463265 | Phase I | |
| Sirolimus + Celecoxib + Etoposide + Cyclophosphamide | NCT02574728 | Phase II | |
| Everolimus + Trametinib | NCT04485559 | Phase I | |
| Melanoma | |||
| Temsirolimus + AZD6244 | NCT00600496 | Phase I | |
| Sarcoma | |||
| Nab-rapamycin + Pazopanib hydrochloride | NCT03660930 | Phase I/II | |
| Temsirolimus + chemotherapy | NCT02567435 | Phase III | |
| Everolimus + Ribociclib | NCT03114527 | Phase II | |
| Everolimus + Temsirolimus + other chemotherapeutic drugs in microdose in implanted percutaneous microdevice | NCT04199026 | Early phase I | |
| Neuroendocrine | |||
| Marketed: neuroendocrine tumors originating in the lungs or gut, pancreatic neuroendocrine tumors (everolimus) | |||
| Everolimus + Lenvatinib | NCT03950609 | Phase II | |
| Everolimus + Bevacizumab + Octreotide acetate | NCT01229943 | Phase II | |
| Others | |||
| Advanced cancer | Rapamycin/Everolimus/Temsirolimus + Vorinostat | NCT01087554 | Phase I |
| Temsirolimus + Bevacizumab + Carboplatin/Sorafenib/Paclitaxel | NCT01187199 | Phase I | |
| Everolimus + Vandetanib | NCT01582191 | Phase I | |
| Rapamycin/Everolimus + Cemiplimab + Prednisone | NCT04339062 | Phase I | |
| Everolimus + Ceritinib | NCT02321501 | Phase I | |
| Solid tumor | Temsirolimus + Ixabepilone | NCT01375829 | Phase I |
| Nab-rapamycin + Temozolomide + Irinotecan | NCT02975882 | Phase I | |
| Temsirolimus + Dasatinib + Cyclophosphamide | NCT02389309 | Phase I | |
| Gedatolisib + Palbociclib | NCT03065062 | Phase I | |
| Temsirolimus + Valproic acid + Cyclophosphamide + Bevacizumab | NCT02446431 | Early phase I | |
| Everolimus + Trametinib + Lenvatinib | NCT04803318 | Phase II | |
| Rapamycin + Epacadostat | NCT03217669 | Phase I | |
| Sirolimus + Celecoxib + Etoposide + Cyclophosphamide | NCT02574728 | Phase II | |
| Neurofibromatosis | Rapamycin + Selumetinib (MEKI) | NCT03433183 | Phase II |
| Rapamycin + PLX3397 (MTKI) | NCT02584647 | Phase I/II | |
| Neuroblastoma | Temsirolimus + Temozolomide + Irinotecan | NCT01767194 | Phase II |
| Hepatoblastoma | Temsirolimus + chemotherapy | NCT00980460 | Phase III |
| Hepatocellular cc | Everolimus + Trametinib + Lenvatinib | NCT04803318 | Phase II |
| Vascular tumor | Rapamycin + Prednisolone | NCT03188068 | Phase II |